About Immutep (NASDAQ:IMMP)
Immutep Ltd, formerly Prima BioMed Ltd., is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The Company is also focused on development of other products, which include IMP701, an antibody for cancer, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer.
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$3.18 million
Price / Sales13.34
Price / CashN/A
Book Value$0.85 per share
Price / Book2.13
Return on EquityN/A
Return on AssetsN/A
Immutep (NASDAQ:IMMP) Frequently Asked Questions
What is Immutep's stock symbol?
Immutep trades on the NASDAQ under the ticker symbol "IMMP."
Where is Immutep's stock going? Where will Immutep's stock price be in 2018?
3 equities research analysts have issued 1-year target prices for Immutep's shares. Their forecasts range from $5.00 to $8.00. On average, they expect Immutep's stock price to reach $6.33 in the next twelve months. View Analyst Ratings for Immutep.
Who are some of Immutep's key competitors?
Some companies that are related to Immutep include Oncomed Pharmaceuticals (OMED), Genocea Biosciences (GNCA), Curis (CRIS), Advaxis (ADXS), Novelion Therapeutics (NVLN), Tissue Regenix Group (TRX), Aptose Biosciences (APTO), OncoSec Medical (ONCS), Senomyx (SNMX), Brainstorm Cell Therapeutics (BCLI), Navidea Biopharmaceuticals (NAVB), NovaBay Pharmaceuticals (NBY), Abzena (ABZA), Scancell (SCLP), CytRx (CYTR), Caladrius Biosciences (CLBS), Cleveland BioLabs (CBLI) and OvaScience (OVAS).
Who are Immutep's key executives?
Immutep's management team includes the folowing people:
- Marc Voigt, Chief Executive Officer, Executive Director (Age 42)
- Deanne Miller, Chief Operating Officer, General Counsel, Company Secretary (Age 39)
- Frederic Triebel M.D., Ph.D., Chief Scientific Officer & Chief Medical Officer (Age 61)
- Russell John Howard Ph.D., Non-Executive Chairman of the Board (Age 65)
- Pete A. Meyers, Non-Executive Deputy Chairman of the Board (Age 47)
- Grant Chamberlain, Non-Executive Director
How do I buy Immutep stock?
Shares of Immutep can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Immutep's stock price today?
One share of Immutep stock can currently be purchased for approximately $1.81.
How big of a company is Immutep?
Immutep has a market capitalization of $42.95 million and generates $3.18 million in revenue each year. Immutep employs 17 workers across the globe.
How can I contact Immutep?
Immutep's mailing address is Plaza Building, L 12 95 Pitt St, SYDNEY, NSW 2000, Australia. The biotechnology company can be reached via phone at +61-2-83157003 or via email at [email protected]
MarketBeat Community Rating for Immutep (IMMP)MarketBeat's community ratings are surveys of what our community members think about Immutep and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Immutep (NASDAQ:IMMP)
No earnings announcements for this company have been tracked by MarketBeat.com
Immutep (NASDAQ:IMMP) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Immutep (NASDAQ:IMMP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Immutep (NASDAQ IMMP)
No insider trades for this company have been tracked by MarketBeat.com
Immutep (NASDAQ IMMP) News Headlines
Immutep (NASDAQ:IMMP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Immutep (NASDAQ:IMMP) Income Statement, Balance Sheet and Cash Flow Statement
Immutep (NASDAQ IMMP) Stock Chart for Friday, February, 23, 2018